Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine the antiviral effect following three days of dosing with BMS-824393 in chronically genotype subtype 1a and 1b Hepatitis C virus (HCV) infected subjects.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Bristol-Myers Squibb
NCT03993925 · Chronic Hepatitis C, Intravenous Drug Usage
NCT00199719 · Chronic Hepatitis C
NCT06922643 · Chronic Hepatitis C
NCT01340573 · Chronic Hepatitis C
NCT01120795 · Chronic Hepatitis C
Advanced Clinical Research Institute
Anaheim, California
West Coast Clinical Trials, Llc
Cypress, California
Elite Research Institute
Miami, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions